Breaking News Instant updates and real-time market news.

GILD

Gilead

$73.90

0.63 (0.86%)

, RAD

Rite Aid

07:35
08/10/17
08/10
07:35
08/10/17
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Wednesday in Gilead (GILD), Rite Aid (RAD), Comcast (CMCSA), Marriott (MAR), TJX (TJX), Wix.com (WIX), Fortuna Silver Mines (FSM), Guess (GES), and Impax (IPXL).

GILD

Gilead

$73.90

0.63 (0.86%)

RAD

Rite Aid

CMCSA

Comcast

$40.63

0.71 (1.78%)

MAR

Marriott

$101.35

-2.6 (-2.50%)

TJX

TJX

$71.26

-0.24 (-0.34%)

WIX

Wix.com

$58.60

-0.05 (-0.09%)

FSM

Fortuna Silver Mines

$4.44

0.09 (2.07%)

GES

Guess

$13.92

-0.19 (-1.35%)

IPXL

Impax

$16.55

1.45 (9.60%)

  • 10

    Aug

  • 10

    Aug

  • 15

    Aug

  • 15

    Aug

  • 16

    Aug

  • 18

    Aug

  • 23

    Aug

  • 28

    Sep

GILD Gilead
$73.90

0.63 (0.86%)

07/14/17
LEER
07/14/17
NO CHANGE
LEER
Acquisition of Incyte would make sense for Gilead, says Leerink
Leerink analyst Geoffrey Porges, who noted he has "written extensively about the imperative for Gilead to diversify their portfolio and secure additional pipeline programs," said in a new note to investors that he believes an acquisition of Incyte (INCY) would make sense for Gilead (GILD). At a "reasonable acquisition premium," Gilead could pay $173-$187 per share for Incyte and its earnings would be diluted through 2018, but thereafter would be increased by such a deal, estimated Porges. The analyst, who concluded that Incyte presents a high-risk/high-reward option for Gilead, keeps a Market perform rating on Gilead shares.
07/13/17
BARD
07/13/17
NO CHANGE
Target $87
BARD
Outperform
Baird likes Gilead heading into Q2 earnings
Baird analyst Brian Skorney said he likes Gilead heading into Q2 earnings. The analyst said Hep-C sales should beat estimates and predicts its sales decline should be approaching a plateau, which would result in upside to the shares. He said the operating results could provide much needed stability, which should also result in upside. Skorney maintained his Outperform rating and $87 price target on Gilead shares.
07/27/17
JPMS
07/27/17
NO CHANGE
Target $85
JPMS
Overweight
Gilead price target raised to $85 from $80 at JPMorgan
JPMorgan analyst Cory Kasimov raised his price target for Gilead Sciences to $85 saying the Q2 beat-and-raise quarter is "encouraging." The HCV franchise is still in decline, but the "resiliency this quarter helps further fuel ample cash generation," Kasimov tells investors in a post-earnings research note. He keeps an Overweight rating on the shares.
07/27/17
COWN
07/27/17
NO CHANGE
Target $90
COWN
Outperform
Gilead results a 'welcome' beat and raise, says Cowen
Cowen analyst Phil Nadeau called the Gilead results a "welcome beat and raise" for what is a very cheap name. The analyst said it may be too early to confidently say the business has stabilized, but his discounted free cash flow analysis suggests the shares remain undervalued. Nadeau reiterated his Outperform rating and $90 price target on Gilead shares.
RAD Rite Aid

06/30/17
06/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Rite Aid (RAD) reinstated with an Underperform at Evercore ISI. 2. Hill-Rom (HRC) initiated with a Buy at Needham and Neutral at Cantor. 3. Dermira (DERM) initiated with an Outperform at Evercore ISI. 4. Coach (COH) initiated with a Buy at Canaccord. 5. WWE (WWE) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/20/17
07/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying he believes the stock's upside drivers are more limited over the next year. 2. Rite Aid (RAD) downgraded to Neutral from Buy at Mizuho. 3. Fairmount Santrol (FMSA) was downgraded to Sell from Neutral at Goldman Sachs and to Neutral from Outperform at Credit Suisse. 4. New Relic (NEWR) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Sanjit Singh saying shares are up 71% year-to-date and valuation captures solid fundamentals but sees fewer catalysts. 5. Smart Sand (SND) downgraded to Neutral from Outperform at Credit Suisse with analyst James Wicklund saying the regional sand volumes capacity is expanding much faster than had been expected. This drives lower pricing and demand for non-Texas mines, he adds. The analyst also lowered his price target on the shares to $8.50 from $20. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/20/17
LEER
07/20/17
NO CHANGE
Target $86
LEER
Outperform
Walgreens, Rite Aid deal still facing 'significant hurdle,' says Leerink
Leerink analyst David Larsen says that even though Walgreens Boots Alliance (WBA) and Rite Aid (RAD) restructured their transaction, he still believes it will be difficult to receive FTC approval. Although the asset purchase agreement may address local market concerns, the FTC will still focus on "national markets" and a declining Rite Aid might actually be another headwind, he argues. Larsen reiterates an Outperform rating and $86 price target on Walgreens' shares.
07/20/17
MZHO
07/20/17
DOWNGRADE
MZHO
Neutral
Rite Aid downgraded to Neutral from Buy at Mizuho
Mizuho analyst Ann Hynes downgraded Rite Aid to Neutral with a $2.95 price target.
CMCSA Comcast
$40.63

0.71 (1.78%)

07/31/17
JPMS
07/31/17
NO CHANGE
Target $450
JPMS
Overweight
Charter offer would likely have to be at least $500 per share, says JPMorgan
JPMorgan analyst Philip Cusick believes SoftBank (SFTBY) is one of the few companies that could offer a big enough price to take control of Charter Communications (CHTR). While a deal is not very likely, Softbank Chairman Masayoshi Son "is never to be counted out as a buyer," Cusick tells investors in a research note. He believes a Charter acquisition offer would likely have to be in the $500 per share or higher range. Charter shares in premarket trading are up $31.74 to $402 after the Wall Street Journal reported Friday night that SoftBank has interest in merging the company with Sprint. Cusick estimates annual synergies between Sprint (S) and Charter could be around $2B, with minimal cost to integrate versus a Sprint and T-Mobile (TMUS) merger "which would have more eventual cost savings but cost much more to integrate." A Sprint and Charter deal would not have a difficult regulatory review, the analyst believes. Cusick adds that if Charter looked like it was going to sell to Softbank, Comcast (CMCSA) would have to decide if it ever did want to buy Charter and "move more quickly with an even bigger premium."
07/26/17
SBSH
07/26/17
NO CHANGE
SBSH
Comcast should acquire Verizon for four reasons, says Citi
Citi analyst Jason Bazinet says Comcast (CMCSA) should acquire Verizon (VZ) for four reasons. Wireless would allow Comcast to extend Internet connectivity beyond the home, the deal would allow the company to push fiber deeper into neighborhoods, Verizon is apt to be the second biggest beneficiary of wireless consolidation, and Comcast could see upside if the tax code changes, Bazinet tells investors in a research note titled "Stars Are Aligning for Comcast + Verizon." The analyst sees the timing for a deal as right given Comcast's history of "trying to acquire assets that have fallen on difficult times" and the potential for a more amendable regulatory landscape under President Trump. Further, 2017 is the first year where Comcast's market capitalization exceeds Verizon's, the analyst adds. He estimates the pro forma combined company would generate $2.1B of annual synergies. Assuming a 20% premium for Verizon's equity, paid via 75% equity and 25% cash, Bazinet estimates Comcast shares would rise to $41. The stock closed yesterday up 28c to $39.75. Bazinet thinks Dish (DISH) could be the biggest loser should Comcast acquire Verizon, and he double downgraded the shares this morning to Sell from Buy.
08/03/17
GUGG
08/03/17
UPGRADE
GUGG
Buy
Comcast upgraded to Buy from Neutral at Guggenheim
Guggenheim analyst Michael Morris upgraded Comcast to Buy and raised its price target to $46 to reflect an attractive valuation, a combination of solid trends at Cable Communications and NBCU content momentum, and strong balance sheet. Morris expects reduced 2018 Cable programming cost growth, advertising momentum, and a strong film slate driving investor interest.
08/03/17
08/03/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Comcast (CMCSA) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris citing an attractive valuation, a combination of solid trends at Cable Communications and NBCU content momentum, and strong balance sheet. 2. Caterpillar (CAT) upgraded to Neutral from Underweight at Atlantic Equities. 3. SodaStream (SODA) upgraded to Positive from Neutral at Susquehanna. 4. Walker & Dunlop (WD) upgraded to Outperform from Market Perform at JMP Securities with analyst Steven DeLaney saying investors may be overly focusing on quarterly results and the reduction in the company's gain on sale margin guidance for the second half of the year. 5. Oshkosh (OSK) upgraded to Neutral from Underperform at BofA/Merrill with analyst Ross Gilardi citing better than expected third quarter results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MAR Marriott
$101.35

-2.6 (-2.50%)

04/26/17
GUGG
04/26/17
INITIATION
GUGG
Neutral
Marriott initiated with a Neutral at Guggenheim
Guggenheim analyst Jake Fuller initiated Marriott with a Neutral saying valuation appears full, industry supply is outpacing demand and RevPAR growth is slowing.
06/27/17
DBAB
06/27/17
NO CHANGE
DBAB
Buy
Deutsche 'incrementally more concerned' on Lodging
Deutsche Bank analyst Carlo Santarelli says he's becoming "incrementally more concerned" regarding Lodging industry fundamentals in the second half of 2017. Trends thus far in the quarter have been soft, but low expectations have allowed the stocks to hang in, Santarelli tells investors in a research note. He thinks investor patience could wane in the second half of 2017 should current trends persist and policy agenda items like corporate tax amendments and healthcare reform continue to linger. The analyst has a Buy rating on Hilton (HLT) and Hold ratings on Choice Hotels (CHH), Hyatt (H) and Marriott (MAR).
08/08/17
SBSH
08/08/17
NO CHANGE
Target $120
SBSH
Buy
Marriott should be bought on pullbacks, says Citi
Citi analyst Smedes Rose says Marriott International's core trends in Q2 were modestly ahead of expectations while its outlook is largely unchanged through the balance of the year. The analyst believes this could drive near-term weakness in shares. Marriott has "numerous levers to outsized earnings growth" going forward and the stock should be bought opportunistically on pullbacks, Rose writes in a post-earnings research note. The analyst keeps a Buy rating on Marriott shares with a $120 price target.
08/08/17
JPMS
08/08/17
NO CHANGE
Target $113
JPMS
Overweight
Marriott target raised to $113 after Q2 results at JPMorgan
JPMorgan analyst Joseph Greff raised his price target for Marriott International shares to $113 from $111 following the company's Q2 results. The analyst continues to see "attractive" 17% annual earnings growth through 2019. He keeps an Overweight rating on Marriott.
TJX TJX
$71.26

-0.24 (-0.34%)

05/17/17
RHCO
05/17/17
NO CHANGE
RHCO
TJX weakness creates buying opportunity, says SunTrust
SunTrust analyst Pamela Quintiliano says that TJX's weaker than expected Q2 guidance is conservative. She thinks that the company's fundamentals are "intact," while its results so far this year are "encouraging." The analyst reiterates a Buy rating.
05/17/17
BMOC
05/17/17
NO CHANGE
BMOC
TJX reported 'solid' Q1 results, says BMO Capital
BMO Capital analyst John Morris says that TJX reported "solid" Q1 results. The analyst notes that the company's Q2 guidance came in below expectations, but he says the company has a history of providing conservative guidance. He remains upbeat on the company's longer term earnings outlook and on the off-price sector. Morris keeps an $85 price target and an Outperform rating on the shares.
08/02/17
FBCO
08/02/17
NO CHANGE
Target $72
FBCO
Neutral
TJX price target lowered to $72 from $79 at Credit Suisse
Credit Suisse analyst Christian Buss lowered his price target for TJX to $72 from $79 as he is incrementally more bearish on TJ Maxx as the company continues to expand square footage despite recent deterioration in return profiles. The analyst reiterates a Neutral rating on the shares.
05/17/17
05/17/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Buy from Hold at Jefferies with analyst Jason Gammel saying the company's divestitures have repaired the balance sheet faster than expected. 2. TJX (TJX) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Kimberly Greensberger saying the pullback in shares following the first quarter comparable store sales miss and soft second quarter guidance creates a buying opportunity. 3. Wolverine World Wide (WWW) upgraded to Outperform from Neutral at Baird with analyst Jonathan Komp citing improving fundamentals, ongoing business initiatives, margin recovery, and an attractive risk/reward. Komp raised his price target to $30 from $29 on Wolverine World Wide shares. 4. Windstream (WIN) upgraded to Outperform from Underperform at Raymond James with analyst Frank Louthan saying the 52% selloff since August 5, 2016 appears overdone given an improved free cash flow outlook from recent acquisitions. 5. Clovis (CLVS) upgraded to Overweight from Neutral at JPMorgan with analyst Cory Kasimov saying the shares are down 35% over the last two months for "no clear fundamental reason." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
WIX Wix.com
$58.60

-0.05 (-0.09%)

07/28/17
NEED
07/28/17
NO CHANGE
Target $86
NEED
Strong Buy
Wix.com selloff a buying opportunity, says Needham
Needham analyst Kerry Rice views the post-earnings weakness in shares of Wix.com as a buying opportunity. With its recent history of beat and raise quarters, a beat and maintain guidance print "comes as a disappointment to some," Rice tells investors in a research note. The analyst continues to expect "strong" revenue and collections growth of 46% and 39%, respectively, as well as FY17 free cash flow to nearly double. The analyst keeps a Buy rating on Wix.com with an $86 price target.
07/24/17
KEYB
07/24/17
INITIATION
Target $88
KEYB
Overweight
Wix.com initiated with an Overweight at KeyBanc
KeyBanc analyst Alyssa Johnson started Wix.com with an Overweight rating and $88 price target. The company is well positioned to take market share across 78M small businesses with its web publishing software, the analyst contends.
06/23/17
06/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Starbucks (SBUX) initiated with an Overweight at KeyBanc. 2. Wix.com (WIX) initiated with an Outperform at Wedbush. 3. Red Hat (RHT) initiated with a Neutral at Piper Jaffray. 4. Amgen (AMGN) initiated with a Hold at Deutsche Bank. 5. Oclaro (OCLR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/17
07/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Blue Apron (APRN) was initiated with a Buy at Goldman Sachs, Stifel, SunTrust, and Canaccord, an Outperform at Oppenheimer and RBC Capital, a Market Perform at William Blair and Raymond James, as well as an Equal Weight at Morgan Stanley and Barclays. 2. Wix.com (WIX) initiated with an Overweight at KeyBanc. 3. Sherwin-Williams (SHW) reinstated with a Neutral at JPMorgan. 4. Aileron Therapeutics (ALRN) was initiated with an Outperform at William Blair, and a Buy at BofA/Merrill, Canaccord, as well as Jefferies. 5. OGE Energy (OGE) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
FSM Fortuna Silver Mines
$4.44

0.09 (2.07%)

03/31/17
BMOC
03/31/17
UPGRADE
BMOC
Outperform
Fortuna Silver Mines upgraded to Outperform from Market Perform at BMO Capital
10/25/16
ADAM
10/25/16
NO CHANGE
ADAM
Buy
Fortuna Silver Mines assumed coverage with a Buy at Canaccord
Canaccord analyst Peter Bure assumed coverage of Fortuna Silver with a Buy rating and $11.50 price target as he believes silver prices will continue to appreciate over the next 12-18 months as zinc and lead mine closures impact supply.
10/24/16
ADAM
10/24/16
UPGRADE
ADAM
Buy
Fortuna Silver upgraded to Buy from Hold at Canaccord
04/05/17
RAJA
04/05/17
UPGRADE
RAJA
Strong Buy
Fortuna Silver Mines upgraded to Strong Buy from Outperform at Raymond James
GES Guess
$13.92

-0.19 (-1.35%)

08/09/17
STPT
08/09/17
DOWNGRADE
STPT
Hold
Guess downgraded to Hold from Buy at Standpoint Research
03/09/17
MZHO
03/09/17
DOWNGRADE
MZHO
Underperform
Guess downgraded to Underperform from Neutral at Mizuho
Mizuho analyst Betty Chen downgraded Guess to Underperform and lowered its price target to $10 from $14. The analyst expects weakness in Americas retail and wholesale to overshadow ongoing momentum in Europe and green shoots in retail. Chen also questions the strategy to rejuvenate the Americas segment and the multi-year retail store rollout strategy in Asia and Europe.
03/10/17
RILY
03/10/17
DOWNGRADE
Target $13.5
RILY
Neutral
Guess downgraded to Neutral from Buy at B. Riley
B. Riley analyst Jeff Van Sinderen downgraded Guess to Neutral citing the slow start to Q1 in the fashion apparel and footwear industry. The analyst lowered his price target for the shares to $13.50 from $17.
08/25/16
08/25/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Netflix (NFLX) upgraded to Outperform from Market Perform at William Blair with analysts led by Ralph Schackart citing its belief the long term risk/reward is favorable. 2. L-3 Communications (LLL) upgraded to Overweight from Neutral at JPMorgan with analyst Seth Seifman saying L-3's turnaround is already underway but sees further free-cash-flow growth and further valuation upside. 3. Guess (GES) upgraded to Buy from Neutral with analyst Jeff Van Sinderen saying he believes the "end game" for Guess will be a sale of the company. 4. Transocean (RIG) upgraded to Neutral from Sell at Citi with analyst Scott Gruber saying the company has exceeded cost reductions while the backlog remains superior to peers. 5. Primoris (PRIM) upgraded to Buy from Neutral at Seaport Global with analyst Ryan Cassil saying there are fairly low expectations assumed in management's guidance of 90c-$1.10 and the possibility of project starts ahead of management's internal forecast. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IPXL Impax
$16.55

1.45 (9.60%)

07/31/17
ADAM
07/31/17
INITIATION
Target $19
ADAM
Hold
Impax initiated with a Hold at Canaccord
Canaccord Genuity analyst Dewey Steadman started Impax Laboratories with a Hold rating and $19 price target. The analyst prefers to wait for a more attractive entry point.
08/10/17
UBSW
08/10/17
NO CHANGE
Target $12
UBSW
Sell
Impax results good but stock ahead of itself, says UBS
UBS analyst Marc Goodman acknowledged Impax reported good Q2 results, but he believes the share price is ahead of itself. He said investors still own the stock in anticipation of a creative, value-additive transaction, but the analyst feels such a scenario is already priced into the valuation. He also feels skeptical of the company's near-term growth drivers, as they too are already in the stock's valuation. Goodman reiterated his Sell rating and $12 price target on Impax shares.
07/18/17
PIPR
07/18/17
UPGRADE
Target $16
PIPR
Neutral
Impax upgraded to Neutral from Underweight at Piper Jaffray
Piper Jaffray analyst David Amsellem upgraded Impax Laboratories to Neutral and raised his price target for the shares to $16 from $9. The company is now better positioned to return to earnings growth following the approval of an AB-rated generic form of Concerta, Amsellem tells investors in a research note. He sees "ample room" for Impax to gain a "significant foothold" in the Concerta market.
06/16/17
CANT
06/16/17
INITIATION
Target $20
CANT
Overweight
Impax initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Impax Laboratories with an Overweight rating and $20 price target.

TODAY'S FREE FLY STORIES

BABA

Alibaba

$159.50

1.75 (1.11%)

, WMT

Wal-Mart

$80.98

0.21 (0.26%)

20:25
08/16/17
08/16
20:25
08/16/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BABA

Alibaba

$159.50

1.75 (1.11%)

WMT

Wal-Mart

$80.98

0.21 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 17

    Aug

  • 17

    Aug

  • 18

    Aug

  • 16

    Nov

  • 20

    Feb

ATU

Actuant

$22.90

-0.2 (-0.87%)

19:22
08/16/17
08/16
19:22
08/16/17
19:22
Hot Stocks
Actuant agrees to divest Viking SeaTech, acquire Mirage Machines »

Actuant Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$46.41

0.9 (1.98%)

19:17
08/16/17
08/16
19:17
08/16/17
19:17
Hot Stocks
Novo Nordisk: SUSTAIN 7 results show superior reduction in HbA1c »

Novo Nordisk announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

GOOG

Alphabet

$926.96

4.74 (0.51%)

, GOOGL

Alphabet Class A

$944.27

6.19 (0.66%)

18:48
08/16/17
08/16
18:48
08/16/17
18:48
Periodicals
Google acquires AIMatter, TechCrunch reports »

Google has acquired…

GOOG

Alphabet

$926.96

4.74 (0.51%)

GOOGL

Alphabet Class A

$944.27

6.19 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 18

    Aug

  • 24

    Aug

SRUN

Silver Run

$10.19

0.01 (0.10%)

18:37
08/16/17
08/16
18:37
08/16/17
18:37
Hot Stocks
Silver Run merging with Alta Mesa and Kingfisher Midstream into $3.8B company »

Silver Run Acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEI

Heico

$85.55

-0.87 (-1.01%)

18:37
08/16/17
08/16
18:37
08/16/17
18:37
Downgrade
Heico rating change at Deutsche Bank »

Heico downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 07

    Sep

GPRK

GeoPark

$8.61

-0.13 (-1.49%)

18:36
08/16/17
08/16
18:36
08/16/17
18:36
Earnings
GeoPark reports Q2 revenue $75.2M, consensus $70.38M »

Reports Q2 consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

MEDP

Medpace

$31.21

-0.16 (-0.51%)

18:14
08/16/17
08/16
18:14
08/16/17
18:14
Hot Stocks
Medpace announces stock repurchase agreement with Cinven »

Medpace Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

TOUR

Tuniu

$7.76

-0.18 (-2.27%)

18:04
08/16/17
08/16
18:04
08/16/17
18:04
Earnings
Tuniu reports Q2 EPS (11c), consensus (26c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

GLDD

Great Lakes Dredge

$3.85

-0.15 (-3.75%)

18:03
08/16/17
08/16
18:03
08/16/17
18:03
Hot Stocks
Great Lakes Dredge CEO acquires 42,610 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TISI

Team

$11.10

-0.25 (-2.20%)

18:00
08/16/17
08/16
18:00
08/16/17
18:00
Hot Stocks
Team director Lois Waters purchases 17,500 shares of company stock »

Team director Lois Waters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$42.41

0.44 (1.05%)

17:59
08/16/17
08/16
17:59
08/16/17
17:59
Hot Stocks
Breaking Hot Stocks news story on NetApp »

NetApp says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

NTAP

NetApp

$42.41

0.44 (1.05%)

17:58
08/16/17
08/16
17:58
08/16/17
17:58
Hot Stocks
Breaking Hot Stocks news story on NetApp »

NetApp says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

NTAP

NetApp

$42.42

0.44 (1.05%)

17:52
08/16/17
08/16
17:52
08/16/17
17:52
Earnings
NetApp sees low double digit EPS growth for FY18, consensus $3.03 »

Sees FY18 adjusted gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

SFST

Southern First Bancshares

$36.00

0.05 (0.14%)

17:50
08/16/17
08/16
17:50
08/16/17
17:50
Hot Stocks
Southern First Bancshares CFO Michael Dowling sells 5,850 shares »

Southern First Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

BXE

Bellatrix Exploration

$2.40

-0.03 (-1.23%)

17:49
08/16/17
08/16
17:49
08/16/17
17:49
Hot Stocks
Bellatrix Exploration regains NYSE minimum price compliance »

Bellatrix Exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$42.41

0.44 (1.05%)

17:48
08/16/17
08/16
17:48
08/16/17
17:48
Hot Stocks
NetApp says headwind for services revenue to decrease in coming quarters »

Comments from Q1 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

ACHN

Achillion

$4.88

-0.12 (-2.40%)

17:45
08/16/17
08/16
17:45
08/16/17
17:45
Conference/Events
Achillion management to meet with William Blair »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

BCOR

Blucora

$23.35

0.1 (0.43%)

, BBOX

Black Box

$3.75

-0.25 (-6.25%)

17:35
08/16/17
08/16
17:35
08/16/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Blucora (BCOR),…

BCOR

Blucora

$23.35

0.1 (0.43%)

BBOX

Black Box

$3.75

-0.25 (-6.25%)

BGG

Briggs & Stratton

$24.09

0.29 (1.22%)

LB

L Brands

$39.55

0.5 (1.28%)

VIPS

Vipshop

$11.10

-0.07 (-0.63%)

SPTN

SpartanNash

$25.96

0.07 (0.27%)

SNPS

Synopsys

$79.09

0.86 (1.10%)

CSCO

Cisco

$32.34

0.25 (0.78%)

NTAP

NetApp

$42.41

0.44 (1.05%)

LAKE

Lakeland Industries

$15.65

-0.25 (-1.57%)

GCP

GCP Applied Technologies

$28.75

0.1 (0.35%)

FNGN

Financial Engines

$34.35

-0.1 (-0.29%)

ACHC

Acadia

$51.68

-0.33 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

  • 16

    Aug

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

  • 29

    Aug

  • 06

    Sep

  • 06

    Sep

  • 06

    Sep

  • 14

    Sep

  • 30

    Nov

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

ANDX

Andeavor Logistics

$46.94

0.12 (0.26%)

, WNRL

Western Refining Logistics

$24.25

0.1 (0.41%)

17:26
08/16/17
08/16
17:26
08/16/17
17:26
Upgrade
Andeavor Logistics, Western Refining Logistics rating change at MUFG »

Andeavor Logistics…

ANDX

Andeavor Logistics

$46.94

0.12 (0.26%)

WNRL

Western Refining Logistics

$24.25

0.1 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$200.61

1.12 (0.56%)

17:22
08/16/17
08/16
17:22
08/16/17
17:22
Hot Stocks
General Dynamics awarded $115.3M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

BLVD

Boulevard Acquisition

$10.04

-0.01 (-0.10%)

17:17
08/16/17
08/16
17:17
08/16/17
17:17
Hot Stocks
Breaking Hot Stocks news story on Boulevard Acquisition »

Glazer Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBH

First Mid-Illinois Bancshares

$34.85

-0.33 (-0.94%)

17:17
08/16/17
08/16
17:17
08/16/17
17:17
Syndicate
First Mid-Illinois Bancshares files to sell $20M of common stock 'at-the-market' »

First Mid-Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

NCOM

National Commerce

$39.55

0.1 (0.25%)

17:16
08/16/17
08/16
17:16
08/16/17
17:16
Hot Stocks
National Commerce, FirstAtlantic Financial sign definitive merger agreement »

National Commerce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMGN

Amgen

$171.39

1.35 (0.79%)

17:13
08/16/17
08/16
17:13
08/16/17
17:13
Hot Stocks
Amgen: NEJM publishes results from Repatha cognitive function trial »

Amgen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

  • 08

    Sep

  • 14

    Sep

  • 02

    Dec

  • 03

    Feb

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.